

Sandrine Aspeslagh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/765158/publications.pdf>

Version: 2024-02-01

50
papers

2,052
citations

279798

23
h-index

243625

44
g-index

51
all docs

51
docs citations

51
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 91-107.	27.6	283
2	Rationale for anti-OX40 cancer immunotherapy. <i>European Journal of Cancer</i> , 2016, 52, 50-66.	2.8	264
3	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. <i>European Journal of Endocrinology</i> , 2019, 181, 363-374.	3.7	154
4	Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. <i>Journal of Cellular Physiology</i> , 2003, 197, 205-213.	4.1	104
5	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. <i>EMBO Journal</i> , 2011, 30, 2294-2305.	7.8	98
6	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
7	Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. <i>Oncotarget</i> , 2017, 8, 80443-80452.	1.8	78
8	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	1.2	73
9	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?: <i>Head and Neck Pathology</i> , 2017, 11, 354-363.	2.6	67
10	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. <i>Current Opinion in Oncology</i> , 2019, 31, 54-64.	2.4	66
11	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	4.5	63
12	Cancer immunotherapy-associated hypophysitis. <i>Seminars in Oncology</i> , 2018, 45, 181-186.	2.2	47
13	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. <i>BMC Cancer</i> , 2019, 19, 506.	2.6	46
14	Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes. <i>Pathology</i> , 2017, 49, 397-404.	0.6	43
15	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. <i>Oncolimmunology</i> , 2017, 6, e1137418.	4.6	42
16	Activated iNKT Cells Promote Memory CD8+ T Cell Differentiation during Viral Infection. <i>PLoS ONE</i> , 2012, 7, e37991.	2.5	38
17	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	1.5	38
18	Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor Protection. <i>Journal of Immunology</i> , 2013, 191, 2916-2925.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Importance of choice of materials and methods in <sc>PD</sc> and <sc>TIL</sc> assessment in oropharyngeal squamous cell carcinoma. <i>Histopathology</i> , 2018, 73, 500-509.	2.9	37
20	Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. <i>European Journal of Endocrinology</i> , 2021, 184, K1-K5.	3.7	37
21	Bacterial CD1d-Restricted Glycolipids Induce IL-10 Production by Human Regulatory T Cells upon Cross-Talk with Invariant NKT Cells. <i>Journal of Immunology</i> , 2013, 191, 2174-2183.	0.8	29
22	Divergent synthetic approach to 6 ² -modified Î±-GalCer analogues. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 8413.	2.8	25
23	Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1257-1265.	2.3	25
24	<i>JAK</i> Mutations as Escape Mechanisms to Anti-PD-1 Therapy. <i>Cancer Discovery</i> , 2017, 7, 128-130.	9.4	24
25	Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model. <i>PLoS ONE</i> , 2013, 8, e65075.	2.5	24
26	CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck. <i>Pathobiology</i> , 2016, 83, 327-333.	3.8	23
27	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. <i>European Journal of Cancer</i> , 2017, 87, 65-74.	2.8	19
28	Invariant natural killer T cells in rheumatic disease: a joint dilemma. <i>Nature Reviews Rheumatology</i> , 2010, 6, 90-98.	8.0	15
29	Synthesis and Evaluation of Amino-Modified Î±-GalCer Analogues. <i>Organic Letters</i> , 2010, 12, 2928-2931.	4.6	14
30	Synthesis of 6 ³ -triazole-substituted Î±-GalCer analogues as potent iNKT cell stimulating ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 7149-7154.	3.0	14
31	Synthesis of C-5 ³ and C-6 ³ -modified Î±-GalCer analogues as iNKT-cell agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3175-3182.	3.0	14
32	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. <i>Melanoma Research</i> , 2021, 31, 371-377.	1.2	12
33	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	1.4	10
34	Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy. <i>Cornea</i> , 2021, 40, 245-247.	1.7	10
35	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	9.6	9
36	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. <i>Journal of Thoracic Oncology</i> , 2016, 11, e21-e23.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 1021-1027.	1.4	7
38	A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder. <i>Case Reports in Oncology</i> , 2021, 14, 861-867.	0.7	7
39	Treatment duration of checkpoint inhibitors for NSCLC. <i>Lancet Respiratory Medicine</i> , 2019, 7, 835-837.	10.7	6
40	Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1701-1703.	1.1	6
41	Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 27-30.	1.4	6
42	An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 524-527.	1.2	5
43	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. <i>Chinese Clinical Oncology</i> , 2015, 4, 48.	1.2	5
44	Eosinophilic Fasciitis in a Patient Treated by Atezolizumab for Metastatic Triple-Negative Breast Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 101-105.	1.4	5
45	Are phase I trials safe for older patients?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 87-92.	1.0	4
46	An In Silico Approach for Modelling T-Helper Polarizing iNKT Cell Agonists. <i>PLoS ONE</i> , 2014, 9, e87000.	2.5	4
47	Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy. <i>Melanoma Research</i> , 2021, 31, 272-276.	1.2	3
48	How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?. <i>Current Opinion in Oncology</i> , 2019, 31, 420-423.	2.4	2
49	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. <i>Acta Clinica Belgica</i> , 2021, 76, 144-148.	1.2	2
50	Preclinical Evaluation of Invariant Natural Killer T-Cells in the 5T33 Multiple Myeloma Model. <i>Blood</i> , 2012, 120, 938-938.	1.4	0